TVGN, TVGNW · CIK 0001860871 · operating
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company developing off-the-shelf precision T cell immunotherapies targeting infectious diseases, cancers, and other disorders. The company's lead candidate, TVGN 489, has completed Phase 1 testing for high-risk ambulatory COVID-19 patients and is in Phase 1 trials for acute SARS-CoV-2 patients with B cell immune suppression, with additional studies underway for Long COVID prevention and treatment. The company maintains a pipeline of preclinical-stage candidates including TVGN 920 for cervical cancer, TVGN 960 for oropharyngeal cancer, TVGN 601 for multiple sclerosis, TVGN 930 for Epstein-Barr virus-associated lymphomas, and TVGN 116 for hepatitis B.
The company is headquartered in Warren, New Jersey and operates with 18 full-time employees. As a pre-revenue clinical-stage entity, Tevogen Bio does not currently generate meaningful revenue from product sales. The company was founded in 2020, incorporated in Delaware, and changed its name to Tevogen Bio Holdings Inc. in February 2024. It is listed on Nasdaq with a market capitalization of $0.1 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.07 | $-0.07 | — | |
| 2023 | — | — | — | |
| 2022 | — | — | — | |
| 2021 | — | — | — |